BMC Neurology (Oct 2021)

Burden of multiple sclerosis in Iran from 1990 to 2017

  • Nima Fattahi,
  • Sahar Saeedi Moghaddam,
  • Farnam Mohebi,
  • Negar Rezaei,
  • Masoud Masinaei,
  • Sahar Mohammadi Fateh,
  • Elham Soleymani Hassanlouei,
  • Farhad Manoochehri,
  • Eghbal Fattahi,
  • Mohammad Ali Sahraian,
  • Maziar Moradi-lakeh,
  • Ali H. Mokdad,
  • Mohsen Naghavi,
  • Farshad Farzadfar

Journal volume & issue
Vol. 21, no. 1
pp. 1 – 10


Read online

Abstract Background Multiple Sclerosis (MS) is a burdensome, chronic and autoimmune disease of the central nervous system. We aimed to report the incidence, prevalence, mortality, and Disability Adjusted Life Years (DALYs) of MS in Iran at a national level for different age and sex groups over a period of 28 years (1990–2017). Methods Data were extracted from the Global Burden of Disease study (GBD) from 1990 to 2017, published by the Institute for Health Metrics and Evaluation. The incidence of DALYs and prevalence of MS were estimated to report the burden of MS based on sex and age in Iran from 1990 to 2017. Results At the national level, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), Age-Standardized DALYs Rate (ASDR) and the Age-Standardized Mortality Rate (ASMR) in Iran in 2017 were 2.4 (95% Uncertainty Interval [UI]: 2.1 to 2.7), 69.5 (62.1 to 77.8), 29.1 (23.6 to 34.7), and 0.4 (0.3 to 0.4) per 100,000 population, respectively. During the period of 1990 to 2017, all measures increased, and were higher among females. The incidence rate began upward trend at the age of 20 and attained its highest level at the age of 25. Conclusion In Iran, all of the age-standardized MS rates have been increasing during the 28 years from 1990 to 2017. Our findings can help policy makers and health planners to design and communicate their plans and to have a better resource allocation, depending on the incidence and prevalence of the growing numbers of MS patients in Iran.